Logo image of CLDI

CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Price, Quote, News and Overview

NYSEARCA:CLDI - NYSE Arca - US3207033099 - Common Stock - Currency: USD

0.4104  0 (-0.87%)

CLDI Quote, Performance and Key Statistics

CALIDI BIOTHERAPEUTICS INC

NYSEARCA:CLDI (5/23/2025, 4:15:02 PM)

0.4104

0 (-0.87%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.9
52 Week Low0.35
Market Cap13.05M
Shares31.79M
Float29.63M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO09-10 2021-09-10


CLDI short term performance overview.The bars show the price performance of CLDI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

CLDI long term performance overview.The bars show the price performance of CLDI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CLDI is 0.4104 USD. In the past month the price decreased by -15.03%. In the past year, price decreased by -82.06%.

CALIDI BIOTHERAPEUTICS INC / CLDI Daily stock chart

CLDI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.84 324.18B
AMGN AMGEN INC 13.09 146.06B
GILD GILEAD SCIENCES INC 13.87 133.68B
VRTX VERTEX PHARMACEUTICALS INC N/A 112.09B
REGN REGENERON PHARMACEUTICALS 13.28 63.52B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.72B
ARGX ARGENX SE - ADR 100.1 35.88B
ONC BEIGENE LTD-ADR 6 26.02B
BNTX BIONTECH SE-ADR N/A 23.72B
NTRA NATERA INC N/A 20.84B
SMMT SUMMIT THERAPEUTICS INC N/A 19.20B
BIIB BIOGEN INC 7.95 18.43B

About CLDI

Company Profile

CLDI logo image Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Company Info

CALIDI BIOTHERAPEUTICS INC

4475 Executive Drive, Suite 200

San Diego CALIFORNIA US

Employees: 28

CLDI Company Website

CLDI Investor Relations

Phone: 18587949600

CALIDI BIOTHERAPEUTICS INC / CLDI FAQ

What is the stock price of CALIDI BIOTHERAPEUTICS INC today?

The current stock price of CLDI is 0.4104 USD. The price decreased by -0.87% in the last trading session.


What is the ticker symbol for CALIDI BIOTHERAPEUTICS INC stock?

The exchange symbol of CALIDI BIOTHERAPEUTICS INC is CLDI and it is listed on the NYSE Arca exchange.


On which exchange is CLDI stock listed?

CLDI stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for CALIDI BIOTHERAPEUTICS INC stock?

7 analysts have analysed CLDI and the average price target is 10.2 USD. This implies a price increase of 2385.38% is expected in the next year compared to the current price of 0.4104. Check the CALIDI BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CALIDI BIOTHERAPEUTICS INC worth?

CALIDI BIOTHERAPEUTICS INC (CLDI) has a market capitalization of 13.05M USD. This makes CLDI a Nano Cap stock.


How many employees does CALIDI BIOTHERAPEUTICS INC have?

CALIDI BIOTHERAPEUTICS INC (CLDI) currently has 28 employees.


What are the support and resistance levels for CALIDI BIOTHERAPEUTICS INC (CLDI) stock?

CALIDI BIOTHERAPEUTICS INC (CLDI) has a support level at 0.41 and a resistance level at 0.42. Check the full technical report for a detailed analysis of CLDI support and resistance levels.


Should I buy CALIDI BIOTHERAPEUTICS INC (CLDI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CALIDI BIOTHERAPEUTICS INC (CLDI) stock pay dividends?

CLDI does not pay a dividend.


What is the Price/Earnings (PE) ratio of CALIDI BIOTHERAPEUTICS INC (CLDI)?

CALIDI BIOTHERAPEUTICS INC (CLDI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.56).


What is the Short Interest ratio of CALIDI BIOTHERAPEUTICS INC (CLDI) stock?

The outstanding short interest for CALIDI BIOTHERAPEUTICS INC (CLDI) is 0.71% of its float. Check the ownership tab for more information on the CLDI short interest.


CLDI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CLDI Financial Highlights

Over the last trailing twelve months CLDI reported a non-GAAP Earnings per Share(EPS) of -4.56.


Industry RankSector Rank
PM (TTM) N/A
ROA -387.44%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%89.38%
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

CLDI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to CLDI. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners4.05%
Ins Owners3.62%
Short Float %0.71%
Short Ratio0.64
Analysts
Analysts85.71
Price Target10.2 (2385.38%)
EPS Next Y87.44%
Revenue Next YearN/A